This site is intended for US healthcare professionals only.

For US healthcare professionals only.

FLOVENT HFA is a maintenance treatment of asthma as preventative therapy in patients aged 4 years and older. FLOVENT HFA is NOT indicated for relief of acute bronchospasm.

Menu

FLOVENT HFA is the #1 most prescribed ICS in the US* and is used as a preventative therapy for asthma in patients aged 4 years and older. FLOVENT HFA is an inhaler that contains fluticasone propionate, a synthetic corticosteroid used to treat asthma symptoms by reducing inflammation in the airways. FLOVENT HFA is not used to relieve sudden breathing problems and will not replace a rescue inhaler.

*IMS Health NPA. US TRx Data. Danbury, CT; Mar 2011-August 2018.

To order, visit our FLOVENT HFA samples and savings offers. You can also click the “Request Samples” button at the top of the page or visit GSK Source. Log in to the GSK Samples and Savings Request Portal and then register. After registration, if you are a licensed practitioner in a relevant specialty, you can select the FLOVENT samples and savings offers you would like to receive. Once you submit your request, you should receive your samples and savings offers within a week.

Log in to the GSK Samples and Savings Request Portal. After you register and submit your request for FLOVENT HFA savings offers, you’ll receive patient coupons in the mail. You can distribute these coupons to your eligible patients and request more coupons once a month.

Patients who are Medicare eligible, or who are enrolled in any federal healthcare program, or who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government prescription drug benefit program for retirees, or who are enrolled in any similar federal or state programs, including state pharmaceutical assistance programs, are NOT eligible. For coupon eligibility purposes, all those 65 or older are considered Medicare eligible.

FLOVENT HFA is available in three strengths — 44 mcg, 110 mcg, and 220 mcg.
The dosing recommended in the FLOVENT HFA Prescribing Information will depend on your patients. The starting dosage is based on previous asthma therapy and asthma severity, including consideration of patients’ current control of asthma symptoms and risk of future exacerbation.

For patients aged 12 years and older who are not on an inhaled corticosteroid, the recommended starting dosage of FLOVENT HFA is 88 mcg twice daily, about 12 hours apart. For other patients, and for patients who do not respond adequately to the starting dosage after two weeks of therapy, higher dosages may provide additional asthma control. The maximum recommended dosage is 880 mcg twice daily, about 12 hours apart. For pediatric patients aged 4 to 11 years, the recommended dosage of FLOVENT HFA is 88 mcg twice daily, about 12 hours apart.

No. The FLOVENT HFA inhaler does not replace a rescue inhaler and should not be used to treat sudden asthma symptoms. If symptoms arise between doses, an inhaled, short-acting beta2-agonist should be used for immediate relief. Patients should be instructed to contact their physicians immediately when episodes of asthma that are not responsive to bronchodilators occur during the course of treatment with FLOVENT HFA.

Currently, there is no AB-rated generic version of FLOVENT HFA available. FLOVENT HFA is the #1 prescribed ICS in the US. For information on FLOVENT HFA coverage for your commercial and Medicare Part D patients, visit our Payer Coverage page.

IMS Health NPA. US TRx Data. Danbury, CT; Mar 2011-August 2018.

According to the results of two placebo-controlled US clinical trials, adverse reactions with FLOVENT HFA (88 mcg, 220 mcg, and 440 mcg of fluticasone propionate) included:

  • Upper respiratory tract infection
  • Throat irritation
  • Upper respiratory inflammation
  • Sinusitis/sinus infection
  • Hoarseness/dysphonia
  • Candidiasis mouth/throat and non–site specific
  • Cough
  • Bronchitis
  • Headache

These results were greater than or equal to 3% incidence and more common than the placebo. The clinical trials included 812 adults and adolescent subjects (457 females and 355 males) who were previously treated with as-needed bronchodilators and/or inhaled corticosteroids. The subjects were treated twice daily for up to 12 weeks. Visit our Adverse Reactions page to learn more.

FLOVENT HFA offers broad formulary coverage nationally as of September 2018, according to the Managed Markets Insight & Technology, LLC, Database. Specifically, 87% of commercial patient lives and 92% of Medicare Part D patient lives have favorable coverage§ nationally. Visit our Medicare Part D Coverage page for additional information. Individual access may vary by geography and plan benefit design. Formulary status is subject to change.

§Favorable coverage is formulary access without restrictions, which means reimbursement from a health plan with no accompanying step edits or prior authorizations.

Important Safety Information

Contraindications

  • FLOVENT HFA is contraindicated for primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

Important Safety Information

Contraindications

  • FLOVENT HFA is contraindicated for primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

  • FLOVENT HFA is contraindicated in patients with hypersensitivity to any of the ingredients of FLOVENT HFA.

Warnings and Precautions

  • Oropharyngeal candidiasis has been observed in clinical studies in patients treated with FLOVENT HFA. Advise patients to rinse the mouth with water without swallowing following inhalation to help reduce the risk of oropharyngeal candidiasis.
  • FLOVENT HFA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta2-agonist, not FLOVENT HFA, should be used to relieve acute symptoms such as shortness of breath.
  • Patients who use corticosteroids are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections.
  • Particular care is needed for patients who have been transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. Taper patients slowly from systemic corticosteroids if transferring to FLOVENT HFA.
  • Hypercorticism and adrenal suppression may occur with high doses of inhaled corticosteroids, including fluticasone propionate, or at the recommended dose in susceptible individuals. If such effects occur, discontinue FLOVENT HFA slowly.
  • Immediate hypersensitivity reactions may occur after administration of FLOVENT HFA. Discontinue FLOVENT HFA if such reactions occur.
  • Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care.
  • Inhaled corticosteroids, as well as poorly controlled asthma, may cause a reduction in growth velocity, and the long-term effect on final adult height is unknown. Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of pediatric patients.
  • Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with asthma following the long‐term administration of inhaled corticosteroids, including FLOVENT HFA. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.
  • If paradoxical bronchospasm occurs, discontinue FLOVENT HFA immediately and institute alternative therapy.
  • The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with FLOVENT HFA is not recommended because increased systemic corticosteroid adverse effects may occur.
  • Be alert to systemic eosinophilic conditions, such as Churg-Strauss syndrome.

Adverse Reactions

  • Most common adverse reactions (incidence >3%) in patients taking FLOVENT HFA 88 mcg twice daily, FLOVENT HFA 220 mcg twice daily, FLOVENT HFA 440 mcg twice daily, and placebo, respectively, were upper respiratory tract infection (18%, 16%, 16%, 14%), throat irritation (8%, 8%, 10%, 5%), upper respiratory inflammation (2%, 5%, 5%, 1%), sinusitis/sinus infection (6%, 7%, 4%, 3%), hoarseness/dysphonia (2%, 3%, 6%, <1%), candidiasis mouth/throat and non-site specific (4%, 2%, 5%, <1%), cough (4%, 6%, 4%, 5%), bronchitis (2%, 2%, 6%, 5%), and headache (11%, 7%, 5%, 6%).

Drug Interactions

  • The use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with FLOVENT HFA is not recommended because increased systemic corticosteroid adverse effects may occur.

Use In Specific Populations

  • Fluticasone propionate is predominantly cleared by hepatic metabolism. Impairment of liver function may lead to accumulation of fluticasone propionate in plasma. Therefore, patients with hepatic disease should be closely monitored.
TOP
Chat